Please wait while the formulary information is being retrieved.
TAKHZYRO (lanadelumab-flyo)
- prevention of angioedema attack in hereditary angioedema
300 mg/2 mL (150 mg/mL) subcutaneous syringe
- Inject 300 mg by subcutaneous route every 4 weeks in the abdomen, thigh, or outer area of upper arm (rotate sites)
Default screening record
- Inject 2 milliliters (300 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or outer area of upper arm (rotate sites)
- Inject 2 milliliters (300 mg) by subcutaneous route every 2 weeks in the abdomen, thigh, or outer area of upper arm (rotate sites)
- Inject 300 mg by subcutaneous route every 4 weeks in the abdomen, thigh, or outer area of upper arm (rotate sites)
- Inject 300 mg by subcutaneous route every 2 weeks in the abdomen, thigh, or outer area of upper arm (rotate sites)
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
TAKHZYRO (lanadelumab-flyo)
- prevention of angioedema attack in hereditary angioedema
- None
- Diarrhea
- Dizziness
- Headache disorder
- Myalgia
- Skin rash
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Hypersensitivity drug reaction
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Lanadelumab-flyo
Safety and effectiveness not established in pediatric patients <12 years.
- 1 Day – 12 Years
- Safety and effectiveness not established in pediatric patients <12 years.
Lanadelumab-flyo
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Lanadelumab-flyo
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Prevention of angioedema attack in hereditary angioedema | |
| D84.1 | Defects in the complement system |
| 0-9 | A-Z |
|---|---|
| D84.1 | Defects in the complement system |
Formulary Reference Tool